Open AccessHIV Nonnucleoside Reverse Transcriptase Inhibitors and Trimethoprim-Sulfamethoxazole Inhibit Plasmodium Liver Stages
Author(s) -
Charlotte V. Hobbs,
Tatiana Voza,
Patricia De La Vega,
Jillian Vanvliet,
Solomon Conteh,
Scott Penzak,
Michael P. Fay,
Nicole M. Anders,
Tiina Ilmet,
Yonghua Li,
William Borkowsky,
Urszula Krzych,
Patrick E. Duffy,
Photini Sinnis
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis602
Subject(s) - plasmodium yoelii , parasitemia , plasmodium berghei , plasmodium falciparum , malaria , biology , virology , plasmodium (life cycle) , pyrimethamine , immunology , pharmacology , parasite hosting , computer science , world wide web
Although nonnucleoside reverse transcriptase inhibitors (NNRTIs) are usually part of first-line treatment regimens for human immunodeficiency virus (HIV), their activity on Plasmodium liver stages remains unexplored. Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infection prophylaxis in HIV-exposed infants and HIV-infected patients, reduces clinical episodes of malaria; however, TMP-SMX effect on Plasmodium liver stages requires further study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom